Nasitrim Duoeffect (Xylometazoline Hydrochloride, Ipratropium Bromide)

Xylometazoline Hydrochloride acts as an alpha‑adrenergic agonist, binding to receptors on nasal blood vessels and causing vasoconstriction. This reduces blood flow to the mucosa, decreasing edema and opening the nasal airway.

The specific dose and frequency are determined by the prescribing healthcare professional based on the patient’s age, condition severity, and response to therapy. Patients should follow the prescriber’s instructions precisely.

Safety information for use in pregnancy or while breastfeeding is limited. Women who are pregnant, planning to become pregnant, or nursing should discuss potential risks and benefits with their healthcare provider before using this product.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Unlike single‑agent decongestants, Nasitrim Duoeffect combines an alpha‑adrenergic agonist with an antimuscarinic, offering both vasoconstriction and reduced secretions. This dual mechanism can provide broader relief of congestion compared with products that contain only one active component.

Store the nasal spray at room temperature, below 25 °C. Keep it in the original packaging, protect it from moisture and direct sunlight, and ensure the cap is tightly closed when not in use.

Nasitrim Duoeffect is administered intranasally. The prescribed number of sprays is delivered into each nostril, typically using the provided metered‑dose pump. Patients should avoid blowing their nose immediately after administration.

Serious risks, though rare, include severe nasal irritation or ulceration, significant hypertension, cardiac arrhythmias, and allergic reactions such as rash, angioedema, or anaphylaxis. Any of these symptoms require immediate medical attention.

Individuals with known hypersensitivity to xylometazoline, ipratropium, or any formulation components should avoid this product. It is also contraindicated in patients with severe hypertension, certain cardiac conditions, or uncontrolled glaucoma without medical supervision.